Sodium taurochenodeoxycholate
CAS No. 6009-98-9
Sodium taurochenodeoxycholate ( —— )
Catalog No. M22823 CAS No. 6009-98-9
Sodium taurochenodeoxycholate is one of the main bioactive substances of animals' bile acid.?Sodium taurochenodeoxycholate induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. It can increase glucose-induced insulin secretion and stimulate the electrical activity of α2-cells and enhance cytosolic Ca(2+) concentration ([Ca(2+)](c)).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | 41 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSodium taurochenodeoxycholate
-
NoteResearch use only, not for human use.
-
Brief DescriptionSodium taurochenodeoxycholate is one of the main bioactive substances of animals' bile acid.?Sodium taurochenodeoxycholate induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. It can increase glucose-induced insulin secretion and stimulate the electrical activity of α2-cells and enhance cytosolic Ca(2+) concentration ([Ca(2+)](c)).
-
DescriptionSodium taurochenodeoxycholate is one of the main bioactive substances of animals' bile acid.?Sodium taurochenodeoxycholate induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. It can increase glucose-induced insulin secretion and stimulate the electrical activity of α2-cells and enhance cytosolic Ca(2+) concentration ([Ca(2+)](c)).Experiments were performed with islets from wild-type, farnesoid X receptor (FXR) knockout (KO), and β-cell ATP-dependent K(+) (K(ATP)) channel gene SUR1 (ABCC8) KO mice, respectively. Sodium taurochenodeoxycholate (TCDC) increased glucose-induced insulin secretion. This effect was mimicked by the FXR agonist GW4064 and suppressed by the FXR antagonist guggulsterone. TCDC and GW4064 stimulated the electrical activity of β-cells and enhanced cytosolic Ca(2+) concentration ([Ca(2+)](c)). These effects were blunted by guggulsterone. Sodium ursodeoxycholate, which has a much lower affinity to FXR than TCDC, had no effect on [Ca(2+)](c) and insulin secretion. FXR activation by TCDC is suggested to inhibit K(ATP) current. The decline in K(ATP) channel activity by TCDC was only observed in β-cells with intact metabolism and was reversed by guggulsterone. TCDC did not alter insulin secretion in islets of SUR1-KO or FXR-KO mice. TCDC did not change islet cell apoptosis.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
Recptorapoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number6009-98-9
-
Formula Weight521.68
-
Molecular FormulaC26H44NNaO6S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition.Diabetes. 2012 Jun;61(6):1479-89.
molnova catalog
related products
-
Mepazine
Mepazine is a potent and selective inhibitor of MALT1. Mepazine inhibits GSTMALT1 full length and GSTMALT1 325-760 with IC50s of 0.83 μM and 0.42 μM.
-
Etalocib
Etalocib is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase.
-
Rigosertib
Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM).